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For most bacteria, getting scooped up 
by macrophages means a rapid death at 
the hands of a lethal cocktail of nitric 
oxide, free radicals, and destructive en-
zymes. Mycobacterium tuberculosis avoids 
this fate first by preventing the fusion of 
phagosomes with lysosomes in resting 
macrophages. The bacterium then turns 
off its replication machinery, allowing it 
to establish a latent infection.
Sabine Ehrt has been grappling with 
M. tuberculosis survival tactics for a decade. 
During her post-doctoral years with Lee 
Riley, first at Weill Cornell Medical 
School (New York) and then at the 
University of California, Berkeley, she 
helped identify some of the mechanisms 
that mycobacteria use to resist the dam-
age caused by free radicals (1).
After moving back to Cornell to 
start her own laboratory, Ehrt focused 
on events that occur before the bacteria 
entrench themselves by focusing on the 
cellular receptors that 
detect infection and 
the signals turned on 
in response (2, 3). 
Along with other 
Cornell microbiolo-
gists, she also explored 
the environment 
within infected phago-
somes by probing the 
transcriptomes of host 
cells and pathogens. 
This effort revealed 
some of the genes and pathways that are 
switched on in infected macrophages 
and provided clues about how myco-
bacteria modify the cells’ transcriptional 
signature (4, 5).
Ehrt’s team has used various genetic 
tricks to identify bacterial mutants that 
cannot combat the macrophages’ toxic-
ity (6). Using a mutagenesis strategy, 
they recently identified a bacterial mem-
brane protein that allows the pathogen 
to resist acidification, which triggers the 
activity of bacteria-killing enzymes (7). 
As bacteria lacking this acid-resisting 
protein are killed easily in vivo, drugs 
that target the protein might help fight 
latent tuberculosis—a disease that affects 
a third of the world’s population.
EAGER TO APPLY
You started your career working on the 
genetics of soil bacteria. How did you get 
interested in that subject?
Like most people who go into research, 
I had always been curious about na-
ture—like why fruits and vegetables have 
their colors, for example. I remember 
trying to isolate carotenes from veggies 
in a little laboratory that I’d set up in 
our bathroom when I was in high 
school. I got interested in genetics after 
that and so for my Masters’ thesis, I 
worked on the tet promoter and its 
recognition by RNA polymerase. But 
for my PhD thesis, I wanted to study 
something that was a little more appli-
cable to real life. So I began a project 
that combined genetics with environ-
mental utility; I tried to identify genes 
that allow a type of soil bacteria to eat 
phenol and other toxic substances and 
degrade them.
Sounds very eco-friendly. What made you 
switch to tuberculosis research?
After I fi  nished my PhD, I realized that I 
liked the applied aspect of science more 
than anything. Now I wanted to do 
something that was medically relevant. It 
was 1994 and tuberculosis had reentered 
our awareness in a big way. I read that 
New York City had had an explosion in 
tuberculosis cases, which motivated me 
to come here to work on this problem. 
My application for post-doctoral work 
was enthusiastically accepted by Lee 
Riley, who was then at Cornell. I also 
got a great fi  ve-year fellowship from the 
German Cancer Research Center that 
would allow me to stay in the US for 
two years and then go back to Germany 
to fi   nish up and become a professor 
there. But I ended up staying in the US 
for the whole time.
ROOTING OUT RESISTANCE
What was your post-doctoral project?
Carl Nathan, who collaborated with Lee, 
had discovered the importance of iNOS—
the enzyme that produces nitric oxide that 
helps kill the pathogen. I tried to fi  nd anti-
oxidant genes in mycobacteria. Lee’s labo-
ratory had already constructed a mycobac-
terial expression library in Escherichia coli. 
The idea was to look for recombinant 
E.coli that had become resistant to nitric 
oxide. A previous post-doc had cloned 
one of these resistance genes, called noxR1, 
and I analyzed its function and helped 
others in the group clone similar genes.
After these resistance mechanisms and 
the genes that drive them had been 
identifi  ed, was there an eff  ort to target 
them for therapy?
No. The problem was that we’d uncov-
ered these mechanisms by expressing my-
cobacterial genes in other organisms; so it 
wasn’t in the right physiological context. 
When the nox genes were deleted in my-
cobacteria, the mutants didn’t have a dra-
matic phenotype, suggesting that there 
were other compensatory mechanisms.
How did you get around this problem?
After I set up my laboratory, we began to 
use transposon mutagenesis to hunt for 
genes in the right genetic context. This 
By fi  guring out how mycobacteria survive within the very cells that try to kill 
them, Ehrt hopes to fi  nd a way to combat chronic tuberculosis infections.
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“The trick to get 
a good answer 
with (transposon 
mutagenesis) is 
to ask the right 
question and use 
the right genetic 
screen.”
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way, we could stay with mycobacteria 
and not transfer genes from these patho-
gens into E.coli or Salmonella.
The trick to get a good answer with 
this approach is to ask the right question 
and use the right genetic screen. Soon af-
ter I came to Cornell, I collaborated with 
Dirk Schnappinger and Gary Schoolnik 
to examine the bacterial transcriptome 
while it resides within the macrophage to 
understand how mycobacteria respond 
to environmental stress. One stress is due 
to low pH, as the phagosome acidifies in 
response to the main macrophage activa-
tor IFNγ. M. tuberculosis would have to 
have some way of defending itself against 
the acidification process to survive. So 
we used a transposon library where one 
gene in each mycobacterium is inter-
rupted by a transposon, and screened this 
library for mutants that couldn’t survive 
acidification. We came up with 21 mu-
tants; one of the mutations was in a gene 
that encodes a membrane protein that 
stabilizes pH within the bacteria even 
when environmental pH is low.
How does this protein do that?
That remains to be seen. Because the 
protein has serine protease activity, it 
might degrade unfolded proteins that 
accumulate in response to acid stress. Or 
it might modify the bacteria’s cell enve-
lope to defend against acidifi  cation.
How does the lack of this protein aff  ect 
bacterial growth?
Knocking out this protein impairs in 
vitro growth when subjected to acid 
stress but not under normal conditions. 
But in mice infected with these mutants, 
both bacterial replication and persis-
tence is impaired. This is important be-
cause tuberculosis is a chronic, persistent 
infection in a majority of people. This 
protein might therefore be a good target 
for drugs to prevent latent infection.
THE POWER OF 
COLLABORATION
Aside from resisting stress, do the 
mycobacteria also infl  uence or modify 
the reactions of the macrophage?
Our collaborators at a biotech company 
helped us address this question by exam-
ining the transcriptomes of infected mac-
rophages while we were studying that of 
the mycobacteria. Macrophages were 
dramatically reprogrammed by mycobac-
terial infection, and molecules such as 
iNOS and other oxidative enzymes that 
were thought to be just defensive turned 
out to also have signaling functions.
Based on these data, we started to 
look at Toll-like receptor (TLR) signals 
in more depth. Our work so far suggests 
that the adaptor MyD88 controls more 
than just TLR signals because mice that 
lack this molecule have much more se-
vere disease than TLR-deficient mice.
Might there be more secrets hidden in 
that transposon library? Have you come 
up with other genes that guide other 
resistance mechanisms?
A post-doc from Carl Nathan’s laboratory, 
Heran Darwin, who actually made the li-
brary, identifi  ed several proteasome-asso-
ciated genes and pathways that help the 
bacteria resist the eff  ects of nitric oxide, 
which suggested that the bacterial protea-
some might contribute to pathogenicity.
Does that mean that the bacteria’s 
proteasome is a valid drug target?
Yes. We’ve demonstrated this by using 
conditional gene silencing to turn off   the 
operon that encodes the proteasome in 
mice after they’ve developed chronic tu-
berculosis. Although the operon isn’t es-
sential for bacterial growth in vitro, the 
bacteria need it to survive during the in-
fection’s chronic phase. The conditional 
knock-down of the operon in the mice 
allowed them to get rid of persistent in-
fection. So Carl’s team is now looking for 
mycobacterial proteasome inhibitors to 
develop into drugs. They’re also looking 
for chemical inhibitors of the acid resis-
tance protein that I mentioned earlier.
Sounds like a productive collaboration.
I’m a big believer in the power of col-
laboration. I’m actually part of a huge 
consortium funded by the Gates Foun-
dation and our goal is to identify drugs 
to treat latent infection. 
While groups like 
mine try to validate 
drug targets in vitro, in 
mice or in nonhuman 
primates, the chemists 
in the consortium as-
sess the molecules for 
their druggability—
whether these com-
pounds can be turned into drugs. I’ve 
learned that working in isolation is not 
benefi   cial. Collaborating not only has 
made science move faster, but also made 
it so much more fun.
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Wild-type M. tuberculosis causes more pathology in mouse lungs (left) than the 
acid-susceptible mutant (right).
“Collaborating 
not only has 
made science 
move faster, but 
also made it so 
much more fun.”